sotorasib,docetaxel
amgen,medsir,sanofi,aventis
['sotorasib', 'nsclc', 'codebreak 200', 'sclc', 'docetaxel', 'medsir']
primary analysis of the phase 3 codebreak 200 trial report superior 1y-pfs (24.8% vs 10.1%) orr (28.1% vs 13.2%) and more favorable safety profile of oral sotorasib vs iv. docetaxel in kras g12c-mutated nsclc. #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM